title: Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.
abstract: BACKGROUND
  The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors.
  
  
  METHODS
  Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine (90 mg/m2) and TBI 200 cGy.
  
  
  RESULTS
  At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease (median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation.
  
  
  CONCLUSIONS
  Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
authors.affiliation: Bone Marrow Transplant Unit, Ospedale San Giovanni Battista, Turin, Italy. abusca@molinette.piemonte.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Busca
authors.forename: Anna
authors.initials: A
authors.lastname: Novarino
authors.forename: Paolo
authors.initials: P
authors.lastname: de Fabritiis
authors.forename: Alessandra
authors.initials: A
authors.lastname: Picardi
authors.forename: Massimo
authors.initials: M
authors.lastname: Zeuli
authors.forename: Franco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Oscar
authors.initials: O
authors.lastname: Bertetto
authors.forename: Michele
authors.initials: M
authors.lastname: Falda
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000601:surgery; D003110:Colonic Neoplasms / Q000473:pathology / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D020350:Graft vs Tumor Effect; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000601:surgery*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data*; D011183:Postoperative Complications; D012004:Rectal Neoplasms / Q000473:pathology / Q000601:surgery; D012509:Sarcoma / Q000556:secondary / Q000601:surgery; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000706:statistics & numerical data; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014916:Whole-Body Irradiation
chemical_list: D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine